ログイン

LMR 4

LMR 4
100問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    : physical agent similar in mechanism to vacuum oven (heat) and agitation to increase movement of molecules and accelerate fixation. It is also used to accelerate staining, decalcification, immunohistochemistry and electron microscopy

    MICROWAVE

  • 2

    temperatures must be maintained between

    70 and 85°C

  • 3

    size of tissue sample is critical (

    2 mm

  • 4

    LAST ALCOHOL BATH FOR DEHYDRATION SHOULD BE

    PURE ETHANOL

  • 5

    A ? discoloration of COPPER SULFATE crystals will indicate FULL SATURATION WITH WATER. Alcohol is then discarded and changed with fresh solution.

    blue

  • 6

    A blue discoloration of ? crystals will indicate FULL SATURATION WITH WATER. Alcohol is then discarded and changed with fresh solution.

    COPPER SULFATE

  • 7

    Skeletal muscle contains bundles of very long, multinucleated cells with cross-striations. Their contraction is quick, forceful, and usually under voluntary control.

    STRIATED, VOLUNTARY

  • 8

    contains bundles of very long, multinucleated cells with cross-striations. Their contraction is quick, forceful, and usually under voluntary control.

    Skeletal muscle

  • 9

    also has cross-striations and is composed of elongated, often branched cells bound to one another at structures called intercalated discs that are unique to cardiac muscle. Contraction is involuntary, vigorous, and rhythmic. STRIATED, INVOLUNTARY

    Cardiac muscle

  • 10

    Cardiac muscle also has cross-striations and is composed of elongated, often branched cells bound to one another at structures called intercalated discs that are unique to cardiac muscle. Contraction is involuntary, vigorous, and rhythmic. ?

    STRIATED, INVOLUNTARY

  • 11

    Cardiac muscle also has cross-striations and is composed of elongated, often branched cells bound to one another at structures called ? that are unique to cardiac muscle. Contraction is involuntary, vigorous, and rhythmic. STRIATED, INVOLUNTARY

    intercalated discs

  • 12

    Smooth muscle consists of collections of fusiform cells that lack striations and have slow, involuntary contractions.

    NONSTRIATED, INVOLUNTARY

  • 13

    ? consists of collections of fusiform cells that lack striations and have slow, involuntary contractions. NONSTRIATED, INVOLUNTARY

    Smooth muscle

  • 14

    : cell death produced by the Tubercle Bacillus. In gross state, the necrotic tissue has the appearance of soft, friable CHEESE.

    CASEOUS NECROSIS

  • 15

    CASEOUS NECROSIS: cell death produced by the Tubercle Bacillus. In gross state, the necrotic tissue has the appearance of soft, friable ?.

    CHEESE

  • 16

    CASEOUS NECROSIS: cell death produced by the ?. In gross state, the necrotic tissue has the appearance of soft, friable CHEESE.

    Tubercle Bacillus

  • 17

    Three (3) major changes that are observed in the NUCLEUS:

    PYKNOSIS, KARYORRHEXIS (segmentation and fragmentation) and KARYOLYSIS (dissolution of the nucleus).

  • 18

    (segmentation and fragmentation)

    KARYORRHEXIS

  • 19

    (dissolution of the nucleus).

    KARYOLYSIS

  • 20

    Four (4) phases or stages of CELL DEGENERATION:

    CLOUDY SWELLING, FATTY DEGENERATION, CELL DEATH OR NECROSIS and CALCIFICATION.

  • 21

    BM aspiration is performed by a physician and may be obtained by: * : most frequently performed method

    Needle biopsy

  • 22

    is performed by a physician and may be obtained by: * Needle biopsy: most frequently performed method * Surgical biopsy * Percutaneous (entering through the skin) TREPINE (small object used to remove circular section of tissue) biopsy (core of bone with accompanying marrow is obtained)

    BM aspiration

  • 23

    (entering through the skin)

    Percutaneous

  • 24

    (small object used to remove circular section of tissue)

    TREPINE

  • 25

    (core of bone with accompanying marrow is obtained)

    biopsy

  • 26

    Antibody enhanced by ACIDIFYING THE PATIENT SERUM:

    anti-M

  • 27

    Most common cause of transfusion reactions:

    CLERICAL ERRORS

  • 28

    Donor unit SEAL HAS BEEN BROKEN:

    DISCARD THE UNIT

  • 29

    Noticeable clots in RBC unit: , indication of contamination or bacterial growth

    DO NOT ISSUE THE UNIT

  • 30

    FIRST STEP in laboratory investigation of transfusion reaction:

    CHECK FOR CLERICAL ERRORS

  • 31

    SAGM, ADSOL shelf life:

    42 days

  • 32

    ? shelf life: 42 days

    SAGM, ADSOL

  • 33

    REJUVENATION or red blood cells may be performed up to ? days after the red cell expire

    3

  • 34

    Preparation of leukopoor RBCs:

    filtering, centrifugation and washing

  • 35

    Longest expiration date:

    FROZEN RBCs

  • 36

    Component of choice for vWD:

    CRYOPRECIPITATE

  • 37

    Transfusion of BUFFY COAT IS BEST INDICATED for: ? with severe infections

    NEWBORNS

  • 38

    Test performed on blood that will be transfused to an acidotic or hypoxic infant:

    HEMOGLOBIN S

  • 39

    CD marker responsible for E-rosette formation between T cells and sheep RBCs:

    CD2

  • 40

    Joining (J) chain:

    IgM and secretory IgA

  • 41

    Ig that helps initiate the classical complement pathway:

    IgM and IgG

  • 42

    Primary immune response:

    IgM

  • 43

    Highest titer in secondary response:

    IgG

  • 44

    Immunoglobulin crosslinks mast cells to release histamine:

    IgE

  • 45

    Substance detected by RPR and VDRL test:

    REAGIN

  • 46

    Substance detected by ? and ? test: REAGIN

    RPR, VDRL

  • 47

    Test for HIV infection in infants who are born to HIV-positive mothers:

    PCR

  • 48

    Best indicator of early acute HBV infection:

    HBsAg

  • 49

    First antibody detected in serum after infection with HBV:

    anti-HBc

  • 50

    Blood products are tested for which virus before being transfused to newborns:

    CMV

  • 51

    Anti-smooth muscle (ASMA) antibodies:

    chronic active hepatitis

  • 52

    : urinary bladder cancer

    Nuclear matrix protein (NMP-22)

  • 53

    Last stage in the erythrocytic series capable of mitosis:

    POLYCHROMATOPHILIC NORMOBLAST

  • 54

    Last nucleated stage in the erythrocytic series:

    ORTHOCHROMATOPHILIC NORMOBLAST

  • 55

    Appearance of primary/nonspecific granules:

    PROMYELOCYTE

  • 56

    Appearance of secondary/specific granules:

    MYELOCYTE

  • 57

    Last stage in the granulocytic series capable of mitosis:

    MYELOCYTE

  • 58

    Youngest cell in the granulocytic series to NORMALLY appear in peripheral blood:

    BAND

  • 59

    . Preferable site for BM aspiration and biopsy in adult:

    ILIAC CREST

  • 60

    . is an ocular device to facilitate counting of: RETICULOCYTES

    Miller disc

  • 61

    . Miller disc is an ocular device to facilitate counting of:

    RETICULOCYTES

  • 62

    Organ that removes erythrocyte inclusions without destroying the cell:

    SPLEEN

  • 63

    Megaloblastic anemia:

    MACROCYTIC, NORMOCHROMIC

  • 64

    : MACROCYTIC, NORMOCHROMIC

    Megaloblastic anemia

  • 65

    Anemia in sickle cell disease:

    NORMOCYTIC, NORMOCHROMIC

  • 66

    Anemia in ? NORMOCYTIC, NORMOCHROMIC

    sickle cell disease:

  • 67

    Iron deficiency anemia, thalassemia:

    MICROCYTIC, HYPOCHROMIC

  • 68

    : MICROCYTIC, HYPOCHROMIC

    Iron deficiency anemia, thalassemia

  • 69

    AUTOSPLENECTOMY occurs in

    SICKLE CELL ANEMIA

  • 70

    occurs in SICKLE CELL ANEMIA

    AUTOSPLENECTOMY

  • 71

    PCH: ?, DONATH-LANDSTEINER ANTIBODY

    Anti-P

  • 72

    Major leukocyte in aplastic anemia:

    LYMPHOCYTES

  • 73

    BITE CELLS in

    G6PD deficiency

  • 74

    in G6PD deficiency

    BITE CELLS

  • 75

    : schistocytes and nucleated RBCs

    Microangiopathic hemolytic anemia

  • 76

    Microangiopathic hemolytic anemia: ? and ?

    schistocytesand nucleated RBCs

  • 77

    ANTIBIOTIC implicated in aplastic anemia:

    CHLORAMPHENICOL

  • 78

    Type of anemia in acute leukemia:

    NORMOCYTIC, NORMOCHROMIC

  • 79

    Hodgkin’s disease:

    REED-STERNBERG CELLS

  • 80

    disease: REED-STERNBERG CELLS

    Hodgkin’s disease

  • 81

    Myelofibrosis: RBCs

    TEARDROP RBCs

  • 82

    : TEARDROP RBCs

    Myelofibrosis

  • 83

    is most often associated with M3: acute promyelocytic leukemia

    DIC

  • 84

    DIC is most often associated with

    M3: acute promyelocytic leukemia

  • 85

    Peripheral smear of patient with MULTIPLE MYELOMA:

    ROULEAUX

  • 86

    Peripheral smear of patient with ?: ROULEAUX

    MULTIPLE MYELOMA

  • 87

    Franklin’s disease: DISEASE

    GAMMA HEAVY CHAIN DISEASE

  • 88

    disease: GAMMA HEAVY CHAIN DISEASE

    Franklin’s disease

  • 89

    TRAP:

    Hairy cell leukemia

  • 90

    : Hairy cell leukemia

    TRAP

  • 91

    CD ?: Common ALL (CALLA)

    10

  • 92

    CD 10:

    Common ALL (CALLA)

  • 93

    PT and APTT result in patient with polycythemia:

    BOTH PROLONGED

  • 94

    PRIMARY INHIBITOR OF FIBRINOLYTIC SYSTEM:

    ALPHA2-ANTIPLASMIN

  • 95

    Lupus anticoagulant is directed against:

    PHOSPHOLIPID

  • 96

    ? anticoagulant is directed against: PHOSPHOLIPID

    Lupus

  • 97

    ASPIRIN inhibits

    CYCLOOXYGENASEHISTOPATH

  • 98

    inhibits CYCLOOXYGENASEHISTOPATH

    ASPIRIN

  • 99

    Primary importance of FROZEN SECTIONS:

    RAPID DIAGNOSIS

  • 100

    3Fs:

    FATS/FORMALIN/FROZEN SECTIONS

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    : physical agent similar in mechanism to vacuum oven (heat) and agitation to increase movement of molecules and accelerate fixation. It is also used to accelerate staining, decalcification, immunohistochemistry and electron microscopy

    MICROWAVE

  • 2

    temperatures must be maintained between

    70 and 85°C

  • 3

    size of tissue sample is critical (

    2 mm

  • 4

    LAST ALCOHOL BATH FOR DEHYDRATION SHOULD BE

    PURE ETHANOL

  • 5

    A ? discoloration of COPPER SULFATE crystals will indicate FULL SATURATION WITH WATER. Alcohol is then discarded and changed with fresh solution.

    blue

  • 6

    A blue discoloration of ? crystals will indicate FULL SATURATION WITH WATER. Alcohol is then discarded and changed with fresh solution.

    COPPER SULFATE

  • 7

    Skeletal muscle contains bundles of very long, multinucleated cells with cross-striations. Their contraction is quick, forceful, and usually under voluntary control.

    STRIATED, VOLUNTARY

  • 8

    contains bundles of very long, multinucleated cells with cross-striations. Their contraction is quick, forceful, and usually under voluntary control.

    Skeletal muscle

  • 9

    also has cross-striations and is composed of elongated, often branched cells bound to one another at structures called intercalated discs that are unique to cardiac muscle. Contraction is involuntary, vigorous, and rhythmic. STRIATED, INVOLUNTARY

    Cardiac muscle

  • 10

    Cardiac muscle also has cross-striations and is composed of elongated, often branched cells bound to one another at structures called intercalated discs that are unique to cardiac muscle. Contraction is involuntary, vigorous, and rhythmic. ?

    STRIATED, INVOLUNTARY

  • 11

    Cardiac muscle also has cross-striations and is composed of elongated, often branched cells bound to one another at structures called ? that are unique to cardiac muscle. Contraction is involuntary, vigorous, and rhythmic. STRIATED, INVOLUNTARY

    intercalated discs

  • 12

    Smooth muscle consists of collections of fusiform cells that lack striations and have slow, involuntary contractions.

    NONSTRIATED, INVOLUNTARY

  • 13

    ? consists of collections of fusiform cells that lack striations and have slow, involuntary contractions. NONSTRIATED, INVOLUNTARY

    Smooth muscle

  • 14

    : cell death produced by the Tubercle Bacillus. In gross state, the necrotic tissue has the appearance of soft, friable CHEESE.

    CASEOUS NECROSIS

  • 15

    CASEOUS NECROSIS: cell death produced by the Tubercle Bacillus. In gross state, the necrotic tissue has the appearance of soft, friable ?.

    CHEESE

  • 16

    CASEOUS NECROSIS: cell death produced by the ?. In gross state, the necrotic tissue has the appearance of soft, friable CHEESE.

    Tubercle Bacillus

  • 17

    Three (3) major changes that are observed in the NUCLEUS:

    PYKNOSIS, KARYORRHEXIS (segmentation and fragmentation) and KARYOLYSIS (dissolution of the nucleus).

  • 18

    (segmentation and fragmentation)

    KARYORRHEXIS

  • 19

    (dissolution of the nucleus).

    KARYOLYSIS

  • 20

    Four (4) phases or stages of CELL DEGENERATION:

    CLOUDY SWELLING, FATTY DEGENERATION, CELL DEATH OR NECROSIS and CALCIFICATION.

  • 21

    BM aspiration is performed by a physician and may be obtained by: * : most frequently performed method

    Needle biopsy

  • 22

    is performed by a physician and may be obtained by: * Needle biopsy: most frequently performed method * Surgical biopsy * Percutaneous (entering through the skin) TREPINE (small object used to remove circular section of tissue) biopsy (core of bone with accompanying marrow is obtained)

    BM aspiration

  • 23

    (entering through the skin)

    Percutaneous

  • 24

    (small object used to remove circular section of tissue)

    TREPINE

  • 25

    (core of bone with accompanying marrow is obtained)

    biopsy

  • 26

    Antibody enhanced by ACIDIFYING THE PATIENT SERUM:

    anti-M

  • 27

    Most common cause of transfusion reactions:

    CLERICAL ERRORS

  • 28

    Donor unit SEAL HAS BEEN BROKEN:

    DISCARD THE UNIT

  • 29

    Noticeable clots in RBC unit: , indication of contamination or bacterial growth

    DO NOT ISSUE THE UNIT

  • 30

    FIRST STEP in laboratory investigation of transfusion reaction:

    CHECK FOR CLERICAL ERRORS

  • 31

    SAGM, ADSOL shelf life:

    42 days

  • 32

    ? shelf life: 42 days

    SAGM, ADSOL

  • 33

    REJUVENATION or red blood cells may be performed up to ? days after the red cell expire

    3

  • 34

    Preparation of leukopoor RBCs:

    filtering, centrifugation and washing

  • 35

    Longest expiration date:

    FROZEN RBCs

  • 36

    Component of choice for vWD:

    CRYOPRECIPITATE

  • 37

    Transfusion of BUFFY COAT IS BEST INDICATED for: ? with severe infections

    NEWBORNS

  • 38

    Test performed on blood that will be transfused to an acidotic or hypoxic infant:

    HEMOGLOBIN S

  • 39

    CD marker responsible for E-rosette formation between T cells and sheep RBCs:

    CD2

  • 40

    Joining (J) chain:

    IgM and secretory IgA

  • 41

    Ig that helps initiate the classical complement pathway:

    IgM and IgG

  • 42

    Primary immune response:

    IgM

  • 43

    Highest titer in secondary response:

    IgG

  • 44

    Immunoglobulin crosslinks mast cells to release histamine:

    IgE

  • 45

    Substance detected by RPR and VDRL test:

    REAGIN

  • 46

    Substance detected by ? and ? test: REAGIN

    RPR, VDRL

  • 47

    Test for HIV infection in infants who are born to HIV-positive mothers:

    PCR

  • 48

    Best indicator of early acute HBV infection:

    HBsAg

  • 49

    First antibody detected in serum after infection with HBV:

    anti-HBc

  • 50

    Blood products are tested for which virus before being transfused to newborns:

    CMV

  • 51

    Anti-smooth muscle (ASMA) antibodies:

    chronic active hepatitis

  • 52

    : urinary bladder cancer

    Nuclear matrix protein (NMP-22)

  • 53

    Last stage in the erythrocytic series capable of mitosis:

    POLYCHROMATOPHILIC NORMOBLAST

  • 54

    Last nucleated stage in the erythrocytic series:

    ORTHOCHROMATOPHILIC NORMOBLAST

  • 55

    Appearance of primary/nonspecific granules:

    PROMYELOCYTE

  • 56

    Appearance of secondary/specific granules:

    MYELOCYTE

  • 57

    Last stage in the granulocytic series capable of mitosis:

    MYELOCYTE

  • 58

    Youngest cell in the granulocytic series to NORMALLY appear in peripheral blood:

    BAND

  • 59

    . Preferable site for BM aspiration and biopsy in adult:

    ILIAC CREST

  • 60

    . is an ocular device to facilitate counting of: RETICULOCYTES

    Miller disc

  • 61

    . Miller disc is an ocular device to facilitate counting of:

    RETICULOCYTES

  • 62

    Organ that removes erythrocyte inclusions without destroying the cell:

    SPLEEN

  • 63

    Megaloblastic anemia:

    MACROCYTIC, NORMOCHROMIC

  • 64

    : MACROCYTIC, NORMOCHROMIC

    Megaloblastic anemia

  • 65

    Anemia in sickle cell disease:

    NORMOCYTIC, NORMOCHROMIC

  • 66

    Anemia in ? NORMOCYTIC, NORMOCHROMIC

    sickle cell disease:

  • 67

    Iron deficiency anemia, thalassemia:

    MICROCYTIC, HYPOCHROMIC

  • 68

    : MICROCYTIC, HYPOCHROMIC

    Iron deficiency anemia, thalassemia

  • 69

    AUTOSPLENECTOMY occurs in

    SICKLE CELL ANEMIA

  • 70

    occurs in SICKLE CELL ANEMIA

    AUTOSPLENECTOMY

  • 71

    PCH: ?, DONATH-LANDSTEINER ANTIBODY

    Anti-P

  • 72

    Major leukocyte in aplastic anemia:

    LYMPHOCYTES

  • 73

    BITE CELLS in

    G6PD deficiency

  • 74

    in G6PD deficiency

    BITE CELLS

  • 75

    : schistocytes and nucleated RBCs

    Microangiopathic hemolytic anemia

  • 76

    Microangiopathic hemolytic anemia: ? and ?

    schistocytesand nucleated RBCs

  • 77

    ANTIBIOTIC implicated in aplastic anemia:

    CHLORAMPHENICOL

  • 78

    Type of anemia in acute leukemia:

    NORMOCYTIC, NORMOCHROMIC

  • 79

    Hodgkin’s disease:

    REED-STERNBERG CELLS

  • 80

    disease: REED-STERNBERG CELLS

    Hodgkin’s disease

  • 81

    Myelofibrosis: RBCs

    TEARDROP RBCs

  • 82

    : TEARDROP RBCs

    Myelofibrosis

  • 83

    is most often associated with M3: acute promyelocytic leukemia

    DIC

  • 84

    DIC is most often associated with

    M3: acute promyelocytic leukemia

  • 85

    Peripheral smear of patient with MULTIPLE MYELOMA:

    ROULEAUX

  • 86

    Peripheral smear of patient with ?: ROULEAUX

    MULTIPLE MYELOMA

  • 87

    Franklin’s disease: DISEASE

    GAMMA HEAVY CHAIN DISEASE

  • 88

    disease: GAMMA HEAVY CHAIN DISEASE

    Franklin’s disease

  • 89

    TRAP:

    Hairy cell leukemia

  • 90

    : Hairy cell leukemia

    TRAP

  • 91

    CD ?: Common ALL (CALLA)

    10

  • 92

    CD 10:

    Common ALL (CALLA)

  • 93

    PT and APTT result in patient with polycythemia:

    BOTH PROLONGED

  • 94

    PRIMARY INHIBITOR OF FIBRINOLYTIC SYSTEM:

    ALPHA2-ANTIPLASMIN

  • 95

    Lupus anticoagulant is directed against:

    PHOSPHOLIPID

  • 96

    ? anticoagulant is directed against: PHOSPHOLIPID

    Lupus

  • 97

    ASPIRIN inhibits

    CYCLOOXYGENASEHISTOPATH

  • 98

    inhibits CYCLOOXYGENASEHISTOPATH

    ASPIRIN

  • 99

    Primary importance of FROZEN SECTIONS:

    RAPID DIAGNOSIS

  • 100

    3Fs:

    FATS/FORMALIN/FROZEN SECTIONS